MedTrace Logo

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

NCT02471105 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2016-05-12

No results posted yet for this study

Summary

This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.

Conditions

Interventions

DRUG

Preserved Bimatoprost 0.01%

Eye drops solution Topical use Once in the evening 3 months

DRUG

Tafluprost Unit Dose Preservative Free 15microgram/ml

Eye drops solution Topical use Once in the evening 3 months

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Ingeborg Stalmans, Phd · UZ Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-05-31
Completion
2017-12-31

Countries

  • Austria
  • Belgium
  • Italy
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471105 on ClinicalTrials.gov